A year marked by solid execution, with
-- Continued UZEDY$(R)$ ramp-up, supporting royalty growth -- Olanzapine LAI advancing into regulatory review ahead of its expected U.S. launch in Q4 2026 by Teva 1 -- The first AbbVie program progressing toward the initiation of clinical development -- The expansion of both partnered and internal R&D pipelines -- Continued strengthening of the technology platform MONTPELLIER, France--(BUSINESS WIRE)--June 16, 2026--
Medincell (Paris:MEDCL):
Key Financial Highlights
------------------------------------------------------------------------------
Total revenues EUR24.3 million, including EUR9.3 million of UZEDY(R)
royalties, confirming the evolution of the revenue
model
Operating result EUR(20.8) million, reflecting a planned increase in
operating expenses to EUR45.0 million (+17%
year-over-year) to support pipeline expansion and
long-term value creation
Liquidity position EUR84.8 million(2) strengthened by successful fund
raising of EUR48.2 million in March 2026, attracting
top-tier US and European healthcare investors
Medincell continues to transition towards multiple commercialized innovative products based on its technology, increasingly supporting milestone and recurring royalty revenues. FY 2025--26 reflects this trend, with strong growth in UZEDY(R) royalties and a disciplined increase in investments to support future growth. As anticipated, year-over-year comparisons are impacted by the absence of non-recurring milestone revenues recorded in the prior year, which affects the comparability of total revenues.
Christophe Douat, CEO of Medincell, said:
"FY 2025--26 reflects an important transition phase for Medincell. Building on UZEDY's strong performance and the expected commercial launch of Olanzapine LAI by our partner Teva later this year, we are advancing the next phase of our 'Shift to Growth' strategy.
We are building a pipeline of highly differentiated, innovation-driven products designed to deliver sustainable value for patients, partners and shareholders, while generating milestones and recurring high-margin revenues over time."
For the full press release, please click on the following link: https://www.medincell.com/news/
About Medincell
Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact.
medincell.com
_______________________________ (1) Subject to regulatory approval (2) Composed of EUR62.8 million in cash and cash equivalents and EUR22.0 million in low-risk financial investments
View source version on businesswire.com: https://www.businesswire.com/news/home/20260616763165/en/
CONTACT: David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86
Grace Kim
Chief Strategy Officer, U.S. Finance
grace.kim@medincell.com / +1 (646) 991-4023
(END) Dow Jones Newswires
June 16, 2026 11:45 ET (15:45 GMT)
Comments